Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 494

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 494
---
 valuation allowance against deferred
tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be
realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position, as well as consideration of the available facts and circumstances. The Company recognizes
interest and penalties related to uncertain tax positions, if any exist, in income tax expense.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding
for the period. Basic and diluted weighted average

F-16

shares of common stock outstanding for the years ended December 31, 2023 and 2022, includes the weighted average effect of 2,426,493 Pre-FundedWarrants (as defined below), which were issued in September 2022, for the purchase of shares of common stock, for which the remaining unfunded exercise price is $0.0001 per share. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities, which include outstanding stock options, restricted stock units, and warrants have been excluded from the computation of diluted net loss per share as they would be anti-dilutive. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

|                                                 |     | Year Ended December 31, |      2023 |     |     |      2022 |
|:------------------------------------------------|:----|:------------------------|----------:|:----|:----|----------:|
| Options to purchase common stock                |     |                         | 4,579,659 |     |     | 2,990,423 |
| Restricted Stock Units to purchase common stock |     |                         |    32,558 |     |     |         — |
| Warrants to purchase common stock               |     |                         |    29,167 |     |     |    29,167 |

Recent